Regulatorische Updates

South Korea, now the world’s second‑largest cosmetics exporter, is focusing on aligning international regulations to avoid new trade hurdles as AI and biotech integrate into products.

At CPHI Korea 2026, experts urged Korean pharma and biotech firms to secure next‑generation modalities, fuse physical AI, and expedite preclinical and data legislation updates.

Intensifying global drug development competition highlights the need for strong patents, timed disclosures and strategic workarounds as China’s fast‑follower biotech sector accelerates patient recruitment and cuts clinical costs.

Pfizer complained about Alnylam’s promotional activities at a cardiology congress, prompting the PMCPA to criticize the biotech, but the UK marketing watchdog later reversed its harshest finding on appeal.